Xenotransplantation Market Size - By Product Type (Organ Preservation Solution, Transplant Diagnostics, Xeno Products), By Application (Kidney, Heart, Liver, Lung), By End-use– Global Forecast to 2032

Xenotransplantation Market Size

Xenotransplantation Market size was valued at USD 12.7 billion in 2022 and is estimated to account for USD 29.9 billion by 2032. Xenotransplantation refers to the transplantation of living cells, tissues, or organs from one species to another, with the transplantation of animal (xenogeneic) organs or tissues into humans. It involves the transfer of biological material across species boundaries to replace or repair damaged or dysfunctional organs in recipients. The objective of xenotransplantation is to address the shortage of human organs available for transplantation by utilizing organs or tissues from non-human animal sources.
 

The rising demand for organ transplantation and the potential of xenotransplantation as a solution will create ample evolution opportunities to the business. For instance, as per the Global Observatory On Donation And Transplantation, more than 144,302 organ transplant procedures were performed in the year 2021. Among which kidney transplants registered highest share with 92,532 procedures worldwide. Moreover, high demand for organ transplants coupled with shortage of organ donors leads to long waiting times and high mortality rates.

COVID-19 Impact

The COVID-19 outbreak negatively impacted the xenotransplantation market. The COVID-19 pandemic had disrupted research activities in many fields, including xenotransplantation. Laboratories and research institutions faced several challenges such as temporary closures, restricted access, reduced funding, and diversion of resources toward COVID-19 research. These disruptions affected the pace of xenotransplantation research and development. The pandemic put immense pressure on healthcare systems worldwide, that led to a shift in priorities toward managing COVID-19 cases and related complications. This shift impacted the allocation of resources and attention to other healthcare areas, including xenotransplantation.
 

Xenotransplantation Market Trends

Advancements in organ preservation technologies, including machine perfusion and cryopreservation methods, enhance the viability and quality of xenogeneic organs.Similarly, advances in genetic engineering techniques, such as CRISPR-Cas9 allows healthcare professionals to modify animal genomes to create genetically engineered pigs or other animals with organs that are more compatible with human recipients. Further, increasing adoption of robotics in minimally invasive surgical techniques will provide potential to improve the precision and safety of xenotransplantation procedures. Robotic-assisted surgery can enhance surgical outcomes and reduce post-operative complications.
 

Xenotransplantation Market Analysis

The xenotransplantation market by product type is segregated into organ preservation solution, transplant diagnostics, xeno product and others. The xeno product segment is further classified into organ, cell, and tissue. The transplant diagnostics segment garnered more than USD 5.4 billion revenue size in the year 2022. Growing chronic diseases burden worldwide leads to surge in the number of organ failure cases. Further, ongoing advancements in diagnostic technologies such as human leukocyte antigen (HLA) typing, non-human leukocyte antigen (nHLA) typing and donor-derived cell-free DNA (dd-cfDNA) testing among others to improve the accuracy, sensitivity, and specificity of detection, facilitating early diagnosis and intervention in the xenotransplantation. Moreover, growing usage of point-of-care testing (POCT) that offers numerous advantages of rapid results, portability, and ease of use and enable real-time monitoring of graft function, rejection, or infectious complications in xenotransplantation.
 

On the basis of application, the xenotransplantation market is classified into kidney, heart, lungs, liver, and others. The kidney segment accounted for over 36% market share in the year 2022. The shortage of human kidneys for transplantation is a major factor driving industry development. The demand for kidney transplantation far exceeds the available supply, leading to long waiting lists and high mortality rates as xenotransplantation offers the possibility of utilizing pig kidneys or other non-human sources to overcome the shortage and provide more options for patients in need of kidney transplantation.
 

Based on end-use, the xenotransplantation market is subdivided into transplant centers, hospitals and others. The transplant centers segment is predicted to witness considerable growth at 8.9% CAGR by 2023. High availability of expertise with experience in organ transplantation, including xenotransplantation coupled with increasing transplant procedures among settings is anticipated to positively influence the industry gains. Additionally, transplant centers with track record of successful patient outcomes, comprehensive multidisciplinary teams, and specialized infrastructure for transplantation procedures. Growing integration of advanced technologies such as utilization of telemedicine, remote monitoring, and digital health platforms to enhance communication, remote patient management, and real-time data analysis in the context of xenotransplantation.
 

U.S. xenotransplantation market accounted for USD 7 billion revenue size in 2022. Growing prevalence of chronic diseases such as end-stage renal disease, heart failure, and liver failure in the U.S. is predicted to positively influence the industry expansion.  Additionally, shortage of organs for transplantation is another factor increasing demand for xenotransplantation. Further, high investment in research and development activities, government initiatives and favourable regulatory policies will boost novel innovations and advancements in the xenotransplantation.
 

Xenotransplantation Market Share

Some of the major market participants operating in the xenotransplantation market include

• Novartis AG
• Immerge BioTherapeutics, Inc.
• United Therapeutics Corporation
• Infigen, Inc.
• eGenesis, Inc.
• NZeno Limited
• Preservation Solutions, Inc.
• Xeno Transplants Corporation
• F. Hoffmann-La Roche Ltd.
• OrganOX Limited 
   

 Xenotransplantation Industry News: 

• In April 2022, eGenesis collaborated with Karius, the leading infectious disease diagnostics provider. This collaboration aimed to develop infectious disease diagnostics for xenotransplantation. Such initiatives strengthen development capabilities of both companies in the significant market.
   
• In January 2022, United Therapeutics Corporation (UT) a public benefit corporation introduced world’s first recipient of an investigational genetically modified xenotransplant organ, UT’s UHeart. This has been designed to provide organs to patients unable to receive human organ donations, offering a competitive edge to the firm.
   

Xenotransplantation market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

By Product Type (USD Million)

• Organ preservation solution
• Transplant diagnostics
• Xeno products
  • Organ
  • Cell
  • Tissue
• Others

By Application (USD Million)

• Kidney
• Heart
• Liver
• Lung
• Others

By End-use (USD Million)

• Transplant centers
• Hospitals
• Others

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Switzerland
  • The Netherlands
  • Denmark
  • Poland
  • Sweden
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • New Zealand
  • Thailand
  • Vietnam
  • Indonesia
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Chile
• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Turkey